Ellor Susan, Shupe Thomas, Petersen Bryon
Department of Pathology, Immunology and Laboratory Medicine; University of Florida.
The Program for Stem Cell Biology and Regenerative Medicine; University of Florida.
Exp Hematol. 2008 Jun;36(6):716-725. doi: 10.1016/j.exphem.2008.02.002. Epub 2008 Apr 2.
Modern medicine has conquered an enormous spectrum of health concerns, from the neonatal to the geriatric, the chronically ill to the acutely injured. Among the unmet challenges remaining in modern medicine are inborn disorders of metabolism within the liver. Such inherited metabolic disorders (IMDs) often leave an otherwise healthy individual with a crippling imbalance. As the principal regulator of the body's many metabolic pathways, malencoded hepatic enzymes can drastically disrupt homeostasis throughout the entire body. Severe phenotypes are usually detected within the first few days of life, and treatments range from palliative lifestyle modifications to aggressive surgical procedures. While orthotopic liver transplantation is the single last resort "cure" for these conditions, research during the past few years has brought new therapeutic technologies ever closer to the clinic. Stem cells, therapeutic viral vectors, or a combination thereof, are projected to be the next, best, and final cure for IMDs, which is well-reflected by this generation's research initiatives.
现代医学已经攻克了从新生儿到老年人、从慢性病患者到急性伤者等广泛的健康问题。现代医学中仍未解决的挑战之一是肝脏的先天性代谢紊乱。这种遗传性代谢紊乱(IMDs)常常使原本健康的个体出现严重的失衡。作为身体许多代谢途径的主要调节者,编码错误的肝脏酶会严重破坏全身的内环境稳定。严重的表型通常在出生后的头几天被检测到,治疗方法从姑息性的生活方式改变到激进的外科手术不等。虽然原位肝移植是这些病症的唯一最终“治愈”方法,但过去几年的研究已使新的治疗技术离临床应用越来越近。干细胞、治疗性病毒载体或它们的组合,预计将成为治疗IMDs的下一个、也是最佳和最终的治愈方法,这在这一代的研究计划中得到了充分体现。